Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)

Intercept Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: OCA 10 mg; Drug: OCA 25 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT01914562

747-104

Details and patient eligibility

About

This is an open label, randomized, balanced, single center, single dose, trial to assess the pharmacokinetic (PK) profile of OCA, glyco-OCA and tauro-OCA on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence, crossover manner.

Enrollment: 32 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Subjects are required to meet the following criteria in order to be included in the trial.

1. Male or female subjects from 18 to 55 years

2. Contraception: Female subjects must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use more than 1 effective (≤ 1% failure rate) method of contraception during the trial and until at least 30 days after the last dose of OCA. Effective methods of contraception are considered to be:

   1. Double barrier method, ie, (a) condom (male or female) with spermicide or (b) diaphragm with spermicide
   2. Intrauterine device (IUD)
   3. Vasectomy

3. Good general health as determined by medical history, and by results of physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests obtained within 14 days prior to Day 0

4. Body mass index (BMI) of 18 to 28; BMI is determined by the following equation: BMI = weight/height2 (kg/m2).

5. Willing to abstain from alcohol, caffeine, and xanthine-containing food and beverages for 72 hours prior to each period check in and during participation of the inpatient periods of the trial

6. Willing and able to give written informed consent

Exclusion criteria

Subjects meeting the following criteria will be excluded from the trial.

1. Prior participation in a clinical trial of OCA (INT-747; 6-ECDCA)
2. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the large intestine, eg, inflammatory bowel disease
3. History of gastrointestinal surgeries or gall bladder removal (cholecystectomy)
4. History or presence of a clinically significant cardiovascular, hepatic, diabetic, gastrointestinal, metabolic, neurologic, pulmonary, endocrine, psychiatric, or neoplastic disorder(s)
5. History of known or suspected clinically significant hypersensitivity to any drug, aside from penicillin
6. Ingestion of a prescription medication within 14 days prior to Day 0 or ingestion of an over the counter medication within 7 days prior to Day 0
7. Participation in radiologic examinations involving parenteral administration of iodinated contrast materials within 2 weeks prior to screening, or subsequently, through the end of trial participation
8. History or presence of alcohol abuse (defined as consumption of more than 210 mL of alcohol per week; or the equivalent of fourteen 4 ounces (oz) glasses of wine, or fourteen 12 oz cans/bottles of beer or wine coolers per week)
9. History or presence of substance abuse within the past 2 years or positive drug screen tests
10. Smoker or user of tobacco or nicotine products
11. Any screening laboratory test for which the results are not within the normal reference range and considered clinically significant
12. Participation in another investigational drug trial within 30 days prior to Day 0
13. History of noncompliance to medical regimens, or subjects who are considered to be potentially unreliable
14. Blood or plasma donation within 30 days prior to Day 0
15. Mental instability or incompetence
16. Presence of human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV) at screening

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

32 participants in 4 patient groups

OCA 10 mg while fasted

Experimental group

Description:

OCA 10 mg orally in the fasting state

Treatment:

Drug: OCA 10 mg

OCA 10 mg while Fed

Experimental group

Description:

OCA 10 mg orally in the fed state

Treatment:

Drug: OCA 10 mg

OCA 25 mg while fasted

Experimental group

Description:

OCA 25 mg orally in the fasting state

Treatment:

Drug: OCA 25 mg

OCA 25 mg while Fed

Experimental group

Description:

OCA 25 mg orally in the fed state

Treatment:

Drug: OCA 25 mg